Global Genetic Testing Market

Genetic Testing Comprehensive Study by Type (Predictive & Presymptomatic Testing, Diagnostic Testing, Carrier Testing, Prenatal Testing, New born screening, Preimplantation Testing, Others), Application (Cancer Genetic Testing, Filling and Capping Machinery, Pharmacogenomics Genetic Testing, Predisposition Cancer Genetic Testing, Others), Clinical Indication (Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anaemia, Duchenne's Muscular Dystrophy, Thalassemia, Huntington’s Disease, Others), End User (Blood Banks, Hospitals, Nursing Homes, Specilaity Clinics, Dignostic Laboratories, Others) Players and Region - Global Market Outlook to 2030

Genetic Testing Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 29%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Genetic Testing
Genetic Testing, also called DNA Testing or genetic analysis, is a medical and scientific procedure that involves examining and analyzing an individual's DNA gain to insight into the individual genetic makeup and genetic information. Genetic testing can reveals specific genetic variations, mutations, or alteration within an individual's genome, providing information about their genetic predispositions, inherited traits, risk of certain diseases, and more. genetic testing is conducted for various purpose, including diagnosing genetic disorder, assessing disease risk, identifying carrier status for inherited condition. genetic testing generally involves the analysis of sample of genetic materials, such as blood, saliva, buccal swabs, or tissue samples, to individual's DNA. Increasing awareness among consumers about advanced diagnostic tests is driving the demand for genetic testing.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR29.0%


The market is fragmented by top global key players who are competing with each other based on strategic development, new product launches and strategic alliances and collaborations between big companies such as Vitrolife partners with Illumina on preimplantation genetic testing business in the genetic testing market in countries like EMEA and Americas. The global genetic testing market is very competitive owing to the presence of well-diversified international and regional players. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Genetic Testing market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Transgenomic, Inc. (United States), GE Healthcare (United States), 23 & Me (United States), Sequenom, Inc. (United States), Abbott Laboratories (United States), Biocartis SA (Switzerland), Illumina Inc. (United States), 454 Life Sciences (United States), Bio-Rad Laboratories (United States), Luminex Corporation (United States), Affymetrix Inc. (United States), Agilent Technologies Inc. (United States), Cephide Inc. (United States), Beckman Coulter Inc. (United States) and Gene Dx LLC (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Invitae (United States), Pathway Genomics (United States), Counsyl, Inc. (United States), Asper Biotech (Europe), GenePlanet (Europe), Ambry Genetics (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Genetic Testing market by Type (Predictive & Presymptomatic Testing, Diagnostic Testing, Carrier Testing, Prenatal Testing, New born screening, Preimplantation Testing and Others), Application (Cancer Genetic Testing, Filling and Capping Machinery, Pharmacogenomics Genetic Testing, Predisposition Cancer Genetic Testing and Others) and Region. On the basis of Type, Diagnostic testing are dominating the market in the year 2023



On the basis of geography, the market of Genetic Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Clinical Indication, the sub-segment i.e. Alzheimer's Disease will boost the Genetic Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Blood Banks will boost the Genetic Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The shift of focus from clinical science to bioinformatics and growing popularity of these techniques, leading to high rate of adoption of genetic testing technology.

Market Growth Drivers:
Increased application of gene testing in Oncological research, The rising prevalence of genetic disorders and Increasing demand for personalized medicine.

Challenges:
Lack of awareness about genetic diseases and testing in several developing regions.

Restraints:
Inaccuracies in results and reimbursement issues and High-cost factor and lack of professional expertise in this market may hamper the market growth rate.

Opportunities:
Genetic tests in conjugation with other genomic technologies helping to predict the risk of an individual to a disease assisting clinicians to select suitable therapeutic interventions. These factors provide opportunities for vendors to grow in pharmaceutical industry.

Market Leaders and their expansionary development strategies
In June 2023, Illumina launched NovaSeq X Plus sequencing system. This new sequencer offered faster and more affordable sequencing, potentially expanding access to genetic testing.
In June 2023, Devyser launched two new products, Devyser LynchFAP and Devyser BRCA PALB2. These kits offer efficient, targeted, and confident analysis of genes associated with increased cancer risk, such as those involved in Lynch syndrome, and breast and ovarian cancers. These genetic testing solutions represent a significant advancement in hereditary cancer offering. By understanding mutations associated with increased cancer risks, ambition is to enable more personalized care and preventive measures, ultimately saving lives."


Key Target Audience
Research Laboratories, Government and regulatory bodies, Healthcare providers, Clinicians, Pharmaceutical companies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Predictive & Presymptomatic Testing
  • Diagnostic Testing
  • Carrier Testing
  • Prenatal Testing
  • New born screening
  • Preimplantation Testing
  • Others
By Application
  • Cancer Genetic Testing
  • Filling and Capping Machinery
  • Pharmacogenomics Genetic Testing
  • Predisposition Cancer Genetic Testing
  • Others
By Clinical Indication
  • Alzheimer's Disease
  • Cancer
  • Cystic Fibrosis
  • Sickle Cell Anaemia
  • Duchenne's Muscular Dystrophy
  • Thalassemia
  • Huntington’s Disease
  • Others

By End User
  • Blood Banks
  • Hospitals
  • Nursing Homes
  • Specilaity Clinics
  • Dignostic Laboratories
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased application of gene testing in Oncological research
      • 3.2.2. The rising prevalence of genetic disorders
      • 3.2.3. Increasing demand for personalized medicine.
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness about genetic diseases and testing in several developing regions.
    • 3.4. Market Trends
      • 3.4.1. The shift of focus from clinical science to bioinformatics and growing popularity of these techniques, leading to high rate of adoption of genetic testing technology.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genetic Testing, by Type, Application, Clinical Indication, End User and Region (value and volume ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Genetic Testing (Value)
      • 5.2.1. Global Genetic Testing by: Type (Value)
        • 5.2.1.1. Predictive & Presymptomatic Testing
        • 5.2.1.2. Diagnostic Testing
        • 5.2.1.3. Carrier Testing
        • 5.2.1.4. Prenatal Testing
        • 5.2.1.5. New born screening
        • 5.2.1.6. Preimplantation Testing
        • 5.2.1.7. Others
      • 5.2.2. Global Genetic Testing by: Application (Value)
        • 5.2.2.1. Cancer Genetic Testing
        • 5.2.2.2. Filling and Capping Machinery
        • 5.2.2.3. Pharmacogenomics Genetic Testing
        • 5.2.2.4. Predisposition Cancer Genetic Testing
        • 5.2.2.5. Others
      • 5.2.3. Global Genetic Testing by: Clinical Indication (Value)
        • 5.2.3.1. Alzheimer's Disease
        • 5.2.3.2. Cancer
        • 5.2.3.3. Cystic Fibrosis
        • 5.2.3.4. Sickle Cell Anaemia
        • 5.2.3.5. Duchenne's Muscular Dystrophy
        • 5.2.3.6. Thalassemia
        • 5.2.3.7. Huntington’s Disease
        • 5.2.3.8. Others
      • 5.2.4. Global Genetic Testing by: End User (Value)
        • 5.2.4.1. Blood Banks
        • 5.2.4.2. Hospitals
        • 5.2.4.3. Nursing Homes
        • 5.2.4.4. Specilaity Clinics
        • 5.2.4.5. Dignostic Laboratories
        • 5.2.4.6. Others
      • 5.2.5. Global Genetic Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Genetic Testing (Volume)
      • 5.3.1. Global Genetic Testing by: Type (Volume)
        • 5.3.1.1. Predictive & Presymptomatic Testing
        • 5.3.1.2. Diagnostic Testing
        • 5.3.1.3. Carrier Testing
        • 5.3.1.4. Prenatal Testing
        • 5.3.1.5. New born screening
        • 5.3.1.6. Preimplantation Testing
        • 5.3.1.7. Others
      • 5.3.2. Global Genetic Testing by: Application (Volume)
        • 5.3.2.1. Cancer Genetic Testing
        • 5.3.2.2. Filling and Capping Machinery
        • 5.3.2.3. Pharmacogenomics Genetic Testing
        • 5.3.2.4. Predisposition Cancer Genetic Testing
        • 5.3.2.5. Others
      • 5.3.3. Global Genetic Testing by: Clinical Indication (Volume)
        • 5.3.3.1. Alzheimer's Disease
        • 5.3.3.2. Cancer
        • 5.3.3.3. Cystic Fibrosis
        • 5.3.3.4. Sickle Cell Anaemia
        • 5.3.3.5. Duchenne's Muscular Dystrophy
        • 5.3.3.6. Thalassemia
        • 5.3.3.7. Huntington’s Disease
        • 5.3.3.8. Others
      • 5.3.4. Global Genetic Testing by: End User (Volume)
        • 5.3.4.1. Blood Banks
        • 5.3.4.2. Hospitals
        • 5.3.4.3. Nursing Homes
        • 5.3.4.4. Specilaity Clinics
        • 5.3.4.5. Dignostic Laboratories
        • 5.3.4.6. Others
      • 5.3.5. Global Genetic Testing Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
  • 6. Genetic Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Transgenomic, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GE Healthcare (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. 23 & Me (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sequenom, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biocartis SA (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Illumina Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. 454 Life Sciences (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio-Rad Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Luminex Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Affymetrix Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Agilent Technologies Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Cephide Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Beckman Coulter Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Gene Dx LLC (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Genetic Testing Sale, by Type, Application, Clinical Indication, End User and Region (value and volume ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Genetic Testing (Value)
      • 7.2.1. Global Genetic Testing by: Type (Value)
        • 7.2.1.1. Predictive & Presymptomatic Testing
        • 7.2.1.2. Diagnostic Testing
        • 7.2.1.3. Carrier Testing
        • 7.2.1.4. Prenatal Testing
        • 7.2.1.5. New born screening
        • 7.2.1.6. Preimplantation Testing
        • 7.2.1.7. Others
      • 7.2.2. Global Genetic Testing by: Application (Value)
        • 7.2.2.1. Cancer Genetic Testing
        • 7.2.2.2. Filling and Capping Machinery
        • 7.2.2.3. Pharmacogenomics Genetic Testing
        • 7.2.2.4. Predisposition Cancer Genetic Testing
        • 7.2.2.5. Others
      • 7.2.3. Global Genetic Testing by: Clinical Indication (Value)
        • 7.2.3.1. Alzheimer's Disease
        • 7.2.3.2. Cancer
        • 7.2.3.3. Cystic Fibrosis
        • 7.2.3.4. Sickle Cell Anaemia
        • 7.2.3.5. Duchenne's Muscular Dystrophy
        • 7.2.3.6. Thalassemia
        • 7.2.3.7. Huntington’s Disease
        • 7.2.3.8. Others
      • 7.2.4. Global Genetic Testing by: End User (Value)
        • 7.2.4.1. Blood Banks
        • 7.2.4.2. Hospitals
        • 7.2.4.3. Nursing Homes
        • 7.2.4.4. Specilaity Clinics
        • 7.2.4.5. Dignostic Laboratories
        • 7.2.4.6. Others
      • 7.2.5. Global Genetic Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Genetic Testing (Volume)
      • 7.3.1. Global Genetic Testing by: Type (Volume)
        • 7.3.1.1. Predictive & Presymptomatic Testing
        • 7.3.1.2. Diagnostic Testing
        • 7.3.1.3. Carrier Testing
        • 7.3.1.4. Prenatal Testing
        • 7.3.1.5. New born screening
        • 7.3.1.6. Preimplantation Testing
        • 7.3.1.7. Others
      • 7.3.2. Global Genetic Testing by: Application (Volume)
        • 7.3.2.1. Cancer Genetic Testing
        • 7.3.2.2. Filling and Capping Machinery
        • 7.3.2.3. Pharmacogenomics Genetic Testing
        • 7.3.2.4. Predisposition Cancer Genetic Testing
        • 7.3.2.5. Others
      • 7.3.3. Global Genetic Testing by: Clinical Indication (Volume)
        • 7.3.3.1. Alzheimer's Disease
        • 7.3.3.2. Cancer
        • 7.3.3.3. Cystic Fibrosis
        • 7.3.3.4. Sickle Cell Anaemia
        • 7.3.3.5. Duchenne's Muscular Dystrophy
        • 7.3.3.6. Thalassemia
        • 7.3.3.7. Huntington’s Disease
        • 7.3.3.8. Others
      • 7.3.4. Global Genetic Testing by: End User (Volume)
        • 7.3.4.1. Blood Banks
        • 7.3.4.2. Hospitals
        • 7.3.4.3. Nursing Homes
        • 7.3.4.4. Specilaity Clinics
        • 7.3.4.5. Dignostic Laboratories
        • 7.3.4.6. Others
      • 7.3.5. Global Genetic Testing Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genetic Testing: by Type(USD Million)
  • Table 2. Genetic Testing Predictive & Presymptomatic Testing , by Region USD Million (2018-2023)
  • Table 3. Genetic Testing Diagnostic Testing , by Region USD Million (2018-2023)
  • Table 4. Genetic Testing Carrier Testing , by Region USD Million (2018-2023)
  • Table 5. Genetic Testing Prenatal Testing , by Region USD Million (2018-2023)
  • Table 6. Genetic Testing New born screening , by Region USD Million (2018-2023)
  • Table 7. Genetic Testing Preimplantation Testing , by Region USD Million (2018-2023)
  • Table 8. Genetic Testing Others , by Region USD Million (2018-2023)
  • Table 9. Genetic Testing: by Application(USD Million)
  • Table 10. Genetic Testing Cancer Genetic Testing , by Region USD Million (2018-2023)
  • Table 11. Genetic Testing Filling and Capping Machinery , by Region USD Million (2018-2023)
  • Table 12. Genetic Testing Pharmacogenomics Genetic Testing , by Region USD Million (2018-2023)
  • Table 13. Genetic Testing Predisposition Cancer Genetic Testing , by Region USD Million (2018-2023)
  • Table 14. Genetic Testing Others , by Region USD Million (2018-2023)
  • Table 15. Genetic Testing: by Clinical Indication(USD Million)
  • Table 16. Genetic Testing Alzheimer's Disease , by Region USD Million (2018-2023)
  • Table 17. Genetic Testing Cancer , by Region USD Million (2018-2023)
  • Table 18. Genetic Testing Cystic Fibrosis , by Region USD Million (2018-2023)
  • Table 19. Genetic Testing Sickle Cell Anaemia , by Region USD Million (2018-2023)
  • Table 20. Genetic Testing Duchenne's Muscular Dystrophy , by Region USD Million (2018-2023)
  • Table 21. Genetic Testing Thalassemia , by Region USD Million (2018-2023)
  • Table 22. Genetic Testing Huntington’s Disease , by Region USD Million (2018-2023)
  • Table 23. Genetic Testing Others , by Region USD Million (2018-2023)
  • Table 24. Genetic Testing: by End User(USD Million)
  • Table 25. Genetic Testing Blood Banks , by Region USD Million (2018-2023)
  • Table 26. Genetic Testing Hospitals , by Region USD Million (2018-2023)
  • Table 27. Genetic Testing Nursing Homes , by Region USD Million (2018-2023)
  • Table 28. Genetic Testing Specilaity Clinics , by Region USD Million (2018-2023)
  • Table 29. Genetic Testing Dignostic Laboratories , by Region USD Million (2018-2023)
  • Table 30. Genetic Testing Others , by Region USD Million (2018-2023)
  • Table 31. South America Genetic Testing, by Country USD Million (2018-2023)
  • Table 32. South America Genetic Testing, by Type USD Million (2018-2023)
  • Table 33. South America Genetic Testing, by Application USD Million (2018-2023)
  • Table 34. South America Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 35. South America Genetic Testing, by End User USD Million (2018-2023)
  • Table 36. Brazil Genetic Testing, by Type USD Million (2018-2023)
  • Table 37. Brazil Genetic Testing, by Application USD Million (2018-2023)
  • Table 38. Brazil Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 39. Brazil Genetic Testing, by End User USD Million (2018-2023)
  • Table 40. Argentina Genetic Testing, by Type USD Million (2018-2023)
  • Table 41. Argentina Genetic Testing, by Application USD Million (2018-2023)
  • Table 42. Argentina Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 43. Argentina Genetic Testing, by End User USD Million (2018-2023)
  • Table 44. Rest of South America Genetic Testing, by Type USD Million (2018-2023)
  • Table 45. Rest of South America Genetic Testing, by Application USD Million (2018-2023)
  • Table 46. Rest of South America Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 47. Rest of South America Genetic Testing, by End User USD Million (2018-2023)
  • Table 48. Asia Pacific Genetic Testing, by Country USD Million (2018-2023)
  • Table 49. Asia Pacific Genetic Testing, by Type USD Million (2018-2023)
  • Table 50. Asia Pacific Genetic Testing, by Application USD Million (2018-2023)
  • Table 51. Asia Pacific Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 52. Asia Pacific Genetic Testing, by End User USD Million (2018-2023)
  • Table 53. China Genetic Testing, by Type USD Million (2018-2023)
  • Table 54. China Genetic Testing, by Application USD Million (2018-2023)
  • Table 55. China Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 56. China Genetic Testing, by End User USD Million (2018-2023)
  • Table 57. Japan Genetic Testing, by Type USD Million (2018-2023)
  • Table 58. Japan Genetic Testing, by Application USD Million (2018-2023)
  • Table 59. Japan Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 60. Japan Genetic Testing, by End User USD Million (2018-2023)
  • Table 61. India Genetic Testing, by Type USD Million (2018-2023)
  • Table 62. India Genetic Testing, by Application USD Million (2018-2023)
  • Table 63. India Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 64. India Genetic Testing, by End User USD Million (2018-2023)
  • Table 65. South Korea Genetic Testing, by Type USD Million (2018-2023)
  • Table 66. South Korea Genetic Testing, by Application USD Million (2018-2023)
  • Table 67. South Korea Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 68. South Korea Genetic Testing, by End User USD Million (2018-2023)
  • Table 69. Taiwan Genetic Testing, by Type USD Million (2018-2023)
  • Table 70. Taiwan Genetic Testing, by Application USD Million (2018-2023)
  • Table 71. Taiwan Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 72. Taiwan Genetic Testing, by End User USD Million (2018-2023)
  • Table 73. Australia Genetic Testing, by Type USD Million (2018-2023)
  • Table 74. Australia Genetic Testing, by Application USD Million (2018-2023)
  • Table 75. Australia Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 76. Australia Genetic Testing, by End User USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Genetic Testing, by Type USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Genetic Testing, by Application USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Genetic Testing, by End User USD Million (2018-2023)
  • Table 81. Europe Genetic Testing, by Country USD Million (2018-2023)
  • Table 82. Europe Genetic Testing, by Type USD Million (2018-2023)
  • Table 83. Europe Genetic Testing, by Application USD Million (2018-2023)
  • Table 84. Europe Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 85. Europe Genetic Testing, by End User USD Million (2018-2023)
  • Table 86. Germany Genetic Testing, by Type USD Million (2018-2023)
  • Table 87. Germany Genetic Testing, by Application USD Million (2018-2023)
  • Table 88. Germany Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 89. Germany Genetic Testing, by End User USD Million (2018-2023)
  • Table 90. France Genetic Testing, by Type USD Million (2018-2023)
  • Table 91. France Genetic Testing, by Application USD Million (2018-2023)
  • Table 92. France Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 93. France Genetic Testing, by End User USD Million (2018-2023)
  • Table 94. Italy Genetic Testing, by Type USD Million (2018-2023)
  • Table 95. Italy Genetic Testing, by Application USD Million (2018-2023)
  • Table 96. Italy Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 97. Italy Genetic Testing, by End User USD Million (2018-2023)
  • Table 98. United Kingdom Genetic Testing, by Type USD Million (2018-2023)
  • Table 99. United Kingdom Genetic Testing, by Application USD Million (2018-2023)
  • Table 100. United Kingdom Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 101. United Kingdom Genetic Testing, by End User USD Million (2018-2023)
  • Table 102. Netherlands Genetic Testing, by Type USD Million (2018-2023)
  • Table 103. Netherlands Genetic Testing, by Application USD Million (2018-2023)
  • Table 104. Netherlands Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 105. Netherlands Genetic Testing, by End User USD Million (2018-2023)
  • Table 106. Rest of Europe Genetic Testing, by Type USD Million (2018-2023)
  • Table 107. Rest of Europe Genetic Testing, by Application USD Million (2018-2023)
  • Table 108. Rest of Europe Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 109. Rest of Europe Genetic Testing, by End User USD Million (2018-2023)
  • Table 110. MEA Genetic Testing, by Country USD Million (2018-2023)
  • Table 111. MEA Genetic Testing, by Type USD Million (2018-2023)
  • Table 112. MEA Genetic Testing, by Application USD Million (2018-2023)
  • Table 113. MEA Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 114. MEA Genetic Testing, by End User USD Million (2018-2023)
  • Table 115. Middle East Genetic Testing, by Type USD Million (2018-2023)
  • Table 116. Middle East Genetic Testing, by Application USD Million (2018-2023)
  • Table 117. Middle East Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 118. Middle East Genetic Testing, by End User USD Million (2018-2023)
  • Table 119. Africa Genetic Testing, by Type USD Million (2018-2023)
  • Table 120. Africa Genetic Testing, by Application USD Million (2018-2023)
  • Table 121. Africa Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 122. Africa Genetic Testing, by End User USD Million (2018-2023)
  • Table 123. North America Genetic Testing, by Country USD Million (2018-2023)
  • Table 124. North America Genetic Testing, by Type USD Million (2018-2023)
  • Table 125. North America Genetic Testing, by Application USD Million (2018-2023)
  • Table 126. North America Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 127. North America Genetic Testing, by End User USD Million (2018-2023)
  • Table 128. United States Genetic Testing, by Type USD Million (2018-2023)
  • Table 129. United States Genetic Testing, by Application USD Million (2018-2023)
  • Table 130. United States Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 131. United States Genetic Testing, by End User USD Million (2018-2023)
  • Table 132. Canada Genetic Testing, by Type USD Million (2018-2023)
  • Table 133. Canada Genetic Testing, by Application USD Million (2018-2023)
  • Table 134. Canada Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 135. Canada Genetic Testing, by End User USD Million (2018-2023)
  • Table 136. Mexico Genetic Testing, by Type USD Million (2018-2023)
  • Table 137. Mexico Genetic Testing, by Application USD Million (2018-2023)
  • Table 138. Mexico Genetic Testing, by Clinical Indication USD Million (2018-2023)
  • Table 139. Mexico Genetic Testing, by End User USD Million (2018-2023)
  • Table 140. Genetic Testing Sales: by Type(K Unit)
  • Table 141. Genetic Testing Sales Predictive & Presymptomatic Testing , by Region K Unit (2018-2023)
  • Table 142. Genetic Testing Sales Diagnostic Testing , by Region K Unit (2018-2023)
  • Table 143. Genetic Testing Sales Carrier Testing , by Region K Unit (2018-2023)
  • Table 144. Genetic Testing Sales Prenatal Testing , by Region K Unit (2018-2023)
  • Table 145. Genetic Testing Sales New born screening , by Region K Unit (2018-2023)
  • Table 146. Genetic Testing Sales Preimplantation Testing , by Region K Unit (2018-2023)
  • Table 147. Genetic Testing Sales Others , by Region K Unit (2018-2023)
  • Table 148. Genetic Testing Sales: by Application(K Unit)
  • Table 149. Genetic Testing Sales Cancer Genetic Testing , by Region K Unit (2018-2023)
  • Table 150. Genetic Testing Sales Filling and Capping Machinery , by Region K Unit (2018-2023)
  • Table 151. Genetic Testing Sales Pharmacogenomics Genetic Testing , by Region K Unit (2018-2023)
  • Table 152. Genetic Testing Sales Predisposition Cancer Genetic Testing , by Region K Unit (2018-2023)
  • Table 153. Genetic Testing Sales Others , by Region K Unit (2018-2023)
  • Table 154. Genetic Testing Sales: by Clinical Indication(K Unit)
  • Table 155. Genetic Testing Sales Alzheimer's Disease , by Region K Unit (2018-2023)
  • Table 156. Genetic Testing Sales Cancer , by Region K Unit (2018-2023)
  • Table 157. Genetic Testing Sales Cystic Fibrosis , by Region K Unit (2018-2023)
  • Table 158. Genetic Testing Sales Sickle Cell Anaemia , by Region K Unit (2018-2023)
  • Table 159. Genetic Testing Sales Duchenne's Muscular Dystrophy , by Region K Unit (2018-2023)
  • Table 160. Genetic Testing Sales Thalassemia , by Region K Unit (2018-2023)
  • Table 161. Genetic Testing Sales Huntington’s Disease , by Region K Unit (2018-2023)
  • Table 162. Genetic Testing Sales Others , by Region K Unit (2018-2023)
  • Table 163. Genetic Testing Sales: by End User(K Unit)
  • Table 164. Genetic Testing Sales Blood Banks , by Region K Unit (2018-2023)
  • Table 165. Genetic Testing Sales Hospitals , by Region K Unit (2018-2023)
  • Table 166. Genetic Testing Sales Nursing Homes , by Region K Unit (2018-2023)
  • Table 167. Genetic Testing Sales Specilaity Clinics , by Region K Unit (2018-2023)
  • Table 168. Genetic Testing Sales Dignostic Laboratories , by Region K Unit (2018-2023)
  • Table 169. Genetic Testing Sales Others , by Region K Unit (2018-2023)
  • Table 170. South America Genetic Testing Sales, by Country K Unit (2018-2023)
  • Table 171. South America Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 172. South America Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 173. South America Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 174. South America Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 175. Brazil Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 176. Brazil Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 177. Brazil Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 178. Brazil Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 179. Argentina Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 180. Argentina Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 181. Argentina Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 182. Argentina Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 183. Rest of South America Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 184. Rest of South America Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 185. Rest of South America Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 186. Rest of South America Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 187. Asia Pacific Genetic Testing Sales, by Country K Unit (2018-2023)
  • Table 188. Asia Pacific Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 189. Asia Pacific Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 190. Asia Pacific Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 191. Asia Pacific Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 192. China Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 193. China Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 194. China Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 195. China Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 196. Japan Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 197. Japan Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 198. Japan Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 199. Japan Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 200. India Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 201. India Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 202. India Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 203. India Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 204. South Korea Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 205. South Korea Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 206. South Korea Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 207. South Korea Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 208. Taiwan Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 209. Taiwan Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 210. Taiwan Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 211. Taiwan Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 212. Australia Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 213. Australia Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 214. Australia Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 215. Australia Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 216. Rest of Asia-Pacific Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 217. Rest of Asia-Pacific Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 218. Rest of Asia-Pacific Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 219. Rest of Asia-Pacific Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 220. Europe Genetic Testing Sales, by Country K Unit (2018-2023)
  • Table 221. Europe Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 222. Europe Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 223. Europe Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 224. Europe Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 225. Germany Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 226. Germany Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 227. Germany Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 228. Germany Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 229. France Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 230. France Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 231. France Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 232. France Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 233. Italy Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 234. Italy Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 235. Italy Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 236. Italy Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 237. United Kingdom Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 238. United Kingdom Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 239. United Kingdom Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 240. United Kingdom Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 241. Netherlands Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 242. Netherlands Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 243. Netherlands Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 244. Netherlands Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 245. Rest of Europe Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 246. Rest of Europe Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 247. Rest of Europe Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 248. Rest of Europe Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 249. MEA Genetic Testing Sales, by Country K Unit (2018-2023)
  • Table 250. MEA Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 251. MEA Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 252. MEA Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 253. MEA Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 254. Middle East Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 255. Middle East Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 256. Middle East Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 257. Middle East Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 258. Africa Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 259. Africa Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 260. Africa Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 261. Africa Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 262. North America Genetic Testing Sales, by Country K Unit (2018-2023)
  • Table 263. North America Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 264. North America Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 265. North America Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 266. North America Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 267. United States Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 268. United States Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 269. United States Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 270. United States Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 271. Canada Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 272. Canada Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 273. Canada Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 274. Canada Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 275. Mexico Genetic Testing Sales, by Type K Unit (2018-2023)
  • Table 276. Mexico Genetic Testing Sales, by Application K Unit (2018-2023)
  • Table 277. Mexico Genetic Testing Sales, by Clinical Indication K Unit (2018-2023)
  • Table 278. Mexico Genetic Testing Sales, by End User K Unit (2018-2023)
  • Table 279. Company Basic Information, Sales Area and Its Competitors
  • Table 280. Company Basic Information, Sales Area and Its Competitors
  • Table 281. Company Basic Information, Sales Area and Its Competitors
  • Table 282. Company Basic Information, Sales Area and Its Competitors
  • Table 283. Company Basic Information, Sales Area and Its Competitors
  • Table 284. Company Basic Information, Sales Area and Its Competitors
  • Table 285. Company Basic Information, Sales Area and Its Competitors
  • Table 286. Company Basic Information, Sales Area and Its Competitors
  • Table 287. Company Basic Information, Sales Area and Its Competitors
  • Table 288. Company Basic Information, Sales Area and Its Competitors
  • Table 289. Company Basic Information, Sales Area and Its Competitors
  • Table 290. Company Basic Information, Sales Area and Its Competitors
  • Table 291. Company Basic Information, Sales Area and Its Competitors
  • Table 292. Company Basic Information, Sales Area and Its Competitors
  • Table 293. Company Basic Information, Sales Area and Its Competitors
  • Table 294. Genetic Testing: by Type(USD Million)
  • Table 295. Genetic Testing Predictive & Presymptomatic Testing , by Region USD Million (2025-2030)
  • Table 296. Genetic Testing Diagnostic Testing , by Region USD Million (2025-2030)
  • Table 297. Genetic Testing Carrier Testing , by Region USD Million (2025-2030)
  • Table 298. Genetic Testing Prenatal Testing , by Region USD Million (2025-2030)
  • Table 299. Genetic Testing New born screening , by Region USD Million (2025-2030)
  • Table 300. Genetic Testing Preimplantation Testing , by Region USD Million (2025-2030)
  • Table 301. Genetic Testing Others , by Region USD Million (2025-2030)
  • Table 302. Genetic Testing: by Application(USD Million)
  • Table 303. Genetic Testing Cancer Genetic Testing , by Region USD Million (2025-2030)
  • Table 304. Genetic Testing Filling and Capping Machinery , by Region USD Million (2025-2030)
  • Table 305. Genetic Testing Pharmacogenomics Genetic Testing , by Region USD Million (2025-2030)
  • Table 306. Genetic Testing Predisposition Cancer Genetic Testing , by Region USD Million (2025-2030)
  • Table 307. Genetic Testing Others , by Region USD Million (2025-2030)
  • Table 308. Genetic Testing: by Clinical Indication(USD Million)
  • Table 309. Genetic Testing Alzheimer's Disease , by Region USD Million (2025-2030)
  • Table 310. Genetic Testing Cancer , by Region USD Million (2025-2030)
  • Table 311. Genetic Testing Cystic Fibrosis , by Region USD Million (2025-2030)
  • Table 312. Genetic Testing Sickle Cell Anaemia , by Region USD Million (2025-2030)
  • Table 313. Genetic Testing Duchenne's Muscular Dystrophy , by Region USD Million (2025-2030)
  • Table 314. Genetic Testing Thalassemia , by Region USD Million (2025-2030)
  • Table 315. Genetic Testing Huntington’s Disease , by Region USD Million (2025-2030)
  • Table 316. Genetic Testing Others , by Region USD Million (2025-2030)
  • Table 317. Genetic Testing: by End User(USD Million)
  • Table 318. Genetic Testing Blood Banks , by Region USD Million (2025-2030)
  • Table 319. Genetic Testing Hospitals , by Region USD Million (2025-2030)
  • Table 320. Genetic Testing Nursing Homes , by Region USD Million (2025-2030)
  • Table 321. Genetic Testing Specilaity Clinics , by Region USD Million (2025-2030)
  • Table 322. Genetic Testing Dignostic Laboratories , by Region USD Million (2025-2030)
  • Table 323. Genetic Testing Others , by Region USD Million (2025-2030)
  • Table 324. South America Genetic Testing, by Country USD Million (2025-2030)
  • Table 325. South America Genetic Testing, by Type USD Million (2025-2030)
  • Table 326. South America Genetic Testing, by Application USD Million (2025-2030)
  • Table 327. South America Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 328. South America Genetic Testing, by End User USD Million (2025-2030)
  • Table 329. Brazil Genetic Testing, by Type USD Million (2025-2030)
  • Table 330. Brazil Genetic Testing, by Application USD Million (2025-2030)
  • Table 331. Brazil Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 332. Brazil Genetic Testing, by End User USD Million (2025-2030)
  • Table 333. Argentina Genetic Testing, by Type USD Million (2025-2030)
  • Table 334. Argentina Genetic Testing, by Application USD Million (2025-2030)
  • Table 335. Argentina Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 336. Argentina Genetic Testing, by End User USD Million (2025-2030)
  • Table 337. Rest of South America Genetic Testing, by Type USD Million (2025-2030)
  • Table 338. Rest of South America Genetic Testing, by Application USD Million (2025-2030)
  • Table 339. Rest of South America Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 340. Rest of South America Genetic Testing, by End User USD Million (2025-2030)
  • Table 341. Asia Pacific Genetic Testing, by Country USD Million (2025-2030)
  • Table 342. Asia Pacific Genetic Testing, by Type USD Million (2025-2030)
  • Table 343. Asia Pacific Genetic Testing, by Application USD Million (2025-2030)
  • Table 344. Asia Pacific Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 345. Asia Pacific Genetic Testing, by End User USD Million (2025-2030)
  • Table 346. China Genetic Testing, by Type USD Million (2025-2030)
  • Table 347. China Genetic Testing, by Application USD Million (2025-2030)
  • Table 348. China Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 349. China Genetic Testing, by End User USD Million (2025-2030)
  • Table 350. Japan Genetic Testing, by Type USD Million (2025-2030)
  • Table 351. Japan Genetic Testing, by Application USD Million (2025-2030)
  • Table 352. Japan Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 353. Japan Genetic Testing, by End User USD Million (2025-2030)
  • Table 354. India Genetic Testing, by Type USD Million (2025-2030)
  • Table 355. India Genetic Testing, by Application USD Million (2025-2030)
  • Table 356. India Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 357. India Genetic Testing, by End User USD Million (2025-2030)
  • Table 358. South Korea Genetic Testing, by Type USD Million (2025-2030)
  • Table 359. South Korea Genetic Testing, by Application USD Million (2025-2030)
  • Table 360. South Korea Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 361. South Korea Genetic Testing, by End User USD Million (2025-2030)
  • Table 362. Taiwan Genetic Testing, by Type USD Million (2025-2030)
  • Table 363. Taiwan Genetic Testing, by Application USD Million (2025-2030)
  • Table 364. Taiwan Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 365. Taiwan Genetic Testing, by End User USD Million (2025-2030)
  • Table 366. Australia Genetic Testing, by Type USD Million (2025-2030)
  • Table 367. Australia Genetic Testing, by Application USD Million (2025-2030)
  • Table 368. Australia Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 369. Australia Genetic Testing, by End User USD Million (2025-2030)
  • Table 370. Rest of Asia-Pacific Genetic Testing, by Type USD Million (2025-2030)
  • Table 371. Rest of Asia-Pacific Genetic Testing, by Application USD Million (2025-2030)
  • Table 372. Rest of Asia-Pacific Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 373. Rest of Asia-Pacific Genetic Testing, by End User USD Million (2025-2030)
  • Table 374. Europe Genetic Testing, by Country USD Million (2025-2030)
  • Table 375. Europe Genetic Testing, by Type USD Million (2025-2030)
  • Table 376. Europe Genetic Testing, by Application USD Million (2025-2030)
  • Table 377. Europe Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 378. Europe Genetic Testing, by End User USD Million (2025-2030)
  • Table 379. Germany Genetic Testing, by Type USD Million (2025-2030)
  • Table 380. Germany Genetic Testing, by Application USD Million (2025-2030)
  • Table 381. Germany Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 382. Germany Genetic Testing, by End User USD Million (2025-2030)
  • Table 383. France Genetic Testing, by Type USD Million (2025-2030)
  • Table 384. France Genetic Testing, by Application USD Million (2025-2030)
  • Table 385. France Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 386. France Genetic Testing, by End User USD Million (2025-2030)
  • Table 387. Italy Genetic Testing, by Type USD Million (2025-2030)
  • Table 388. Italy Genetic Testing, by Application USD Million (2025-2030)
  • Table 389. Italy Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 390. Italy Genetic Testing, by End User USD Million (2025-2030)
  • Table 391. United Kingdom Genetic Testing, by Type USD Million (2025-2030)
  • Table 392. United Kingdom Genetic Testing, by Application USD Million (2025-2030)
  • Table 393. United Kingdom Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 394. United Kingdom Genetic Testing, by End User USD Million (2025-2030)
  • Table 395. Netherlands Genetic Testing, by Type USD Million (2025-2030)
  • Table 396. Netherlands Genetic Testing, by Application USD Million (2025-2030)
  • Table 397. Netherlands Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 398. Netherlands Genetic Testing, by End User USD Million (2025-2030)
  • Table 399. Rest of Europe Genetic Testing, by Type USD Million (2025-2030)
  • Table 400. Rest of Europe Genetic Testing, by Application USD Million (2025-2030)
  • Table 401. Rest of Europe Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 402. Rest of Europe Genetic Testing, by End User USD Million (2025-2030)
  • Table 403. MEA Genetic Testing, by Country USD Million (2025-2030)
  • Table 404. MEA Genetic Testing, by Type USD Million (2025-2030)
  • Table 405. MEA Genetic Testing, by Application USD Million (2025-2030)
  • Table 406. MEA Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 407. MEA Genetic Testing, by End User USD Million (2025-2030)
  • Table 408. Middle East Genetic Testing, by Type USD Million (2025-2030)
  • Table 409. Middle East Genetic Testing, by Application USD Million (2025-2030)
  • Table 410. Middle East Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 411. Middle East Genetic Testing, by End User USD Million (2025-2030)
  • Table 412. Africa Genetic Testing, by Type USD Million (2025-2030)
  • Table 413. Africa Genetic Testing, by Application USD Million (2025-2030)
  • Table 414. Africa Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 415. Africa Genetic Testing, by End User USD Million (2025-2030)
  • Table 416. North America Genetic Testing, by Country USD Million (2025-2030)
  • Table 417. North America Genetic Testing, by Type USD Million (2025-2030)
  • Table 418. North America Genetic Testing, by Application USD Million (2025-2030)
  • Table 419. North America Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 420. North America Genetic Testing, by End User USD Million (2025-2030)
  • Table 421. United States Genetic Testing, by Type USD Million (2025-2030)
  • Table 422. United States Genetic Testing, by Application USD Million (2025-2030)
  • Table 423. United States Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 424. United States Genetic Testing, by End User USD Million (2025-2030)
  • Table 425. Canada Genetic Testing, by Type USD Million (2025-2030)
  • Table 426. Canada Genetic Testing, by Application USD Million (2025-2030)
  • Table 427. Canada Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 428. Canada Genetic Testing, by End User USD Million (2025-2030)
  • Table 429. Mexico Genetic Testing, by Type USD Million (2025-2030)
  • Table 430. Mexico Genetic Testing, by Application USD Million (2025-2030)
  • Table 431. Mexico Genetic Testing, by Clinical Indication USD Million (2025-2030)
  • Table 432. Mexico Genetic Testing, by End User USD Million (2025-2030)
  • Table 433. Genetic Testing Sales: by Type(K Unit)
  • Table 434. Genetic Testing Sales Predictive & Presymptomatic Testing , by Region K Unit (2025-2030)
  • Table 435. Genetic Testing Sales Diagnostic Testing , by Region K Unit (2025-2030)
  • Table 436. Genetic Testing Sales Carrier Testing , by Region K Unit (2025-2030)
  • Table 437. Genetic Testing Sales Prenatal Testing , by Region K Unit (2025-2030)
  • Table 438. Genetic Testing Sales New born screening , by Region K Unit (2025-2030)
  • Table 439. Genetic Testing Sales Preimplantation Testing , by Region K Unit (2025-2030)
  • Table 440. Genetic Testing Sales Others , by Region K Unit (2025-2030)
  • Table 441. Genetic Testing Sales: by Application(K Unit)
  • Table 442. Genetic Testing Sales Cancer Genetic Testing , by Region K Unit (2025-2030)
  • Table 443. Genetic Testing Sales Filling and Capping Machinery , by Region K Unit (2025-2030)
  • Table 444. Genetic Testing Sales Pharmacogenomics Genetic Testing , by Region K Unit (2025-2030)
  • Table 445. Genetic Testing Sales Predisposition Cancer Genetic Testing , by Region K Unit (2025-2030)
  • Table 446. Genetic Testing Sales Others , by Region K Unit (2025-2030)
  • Table 447. Genetic Testing Sales: by Clinical Indication(K Unit)
  • Table 448. Genetic Testing Sales Alzheimer's Disease , by Region K Unit (2025-2030)
  • Table 449. Genetic Testing Sales Cancer , by Region K Unit (2025-2030)
  • Table 450. Genetic Testing Sales Cystic Fibrosis , by Region K Unit (2025-2030)
  • Table 451. Genetic Testing Sales Sickle Cell Anaemia , by Region K Unit (2025-2030)
  • Table 452. Genetic Testing Sales Duchenne's Muscular Dystrophy , by Region K Unit (2025-2030)
  • Table 453. Genetic Testing Sales Thalassemia , by Region K Unit (2025-2030)
  • Table 454. Genetic Testing Sales Huntington’s Disease , by Region K Unit (2025-2030)
  • Table 455. Genetic Testing Sales Others , by Region K Unit (2025-2030)
  • Table 456. Genetic Testing Sales: by End User(K Unit)
  • Table 457. Genetic Testing Sales Blood Banks , by Region K Unit (2025-2030)
  • Table 458. Genetic Testing Sales Hospitals , by Region K Unit (2025-2030)
  • Table 459. Genetic Testing Sales Nursing Homes , by Region K Unit (2025-2030)
  • Table 460. Genetic Testing Sales Specilaity Clinics , by Region K Unit (2025-2030)
  • Table 461. Genetic Testing Sales Dignostic Laboratories , by Region K Unit (2025-2030)
  • Table 462. Genetic Testing Sales Others , by Region K Unit (2025-2030)
  • Table 463. South America Genetic Testing Sales, by Country K Unit (2025-2030)
  • Table 464. South America Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 465. South America Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 466. South America Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 467. South America Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 468. Brazil Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 469. Brazil Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 470. Brazil Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 471. Brazil Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 472. Argentina Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 473. Argentina Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 474. Argentina Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 475. Argentina Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 476. Rest of South America Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 477. Rest of South America Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 478. Rest of South America Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 479. Rest of South America Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 480. Asia Pacific Genetic Testing Sales, by Country K Unit (2025-2030)
  • Table 481. Asia Pacific Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 482. Asia Pacific Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 483. Asia Pacific Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 484. Asia Pacific Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 485. China Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 486. China Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 487. China Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 488. China Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 489. Japan Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 490. Japan Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 491. Japan Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 492. Japan Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 493. India Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 494. India Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 495. India Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 496. India Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 497. South Korea Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 498. South Korea Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 499. South Korea Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 500. South Korea Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 501. Taiwan Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 502. Taiwan Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 503. Taiwan Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 504. Taiwan Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 505. Australia Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 506. Australia Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 507. Australia Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 508. Australia Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 509. Rest of Asia-Pacific Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 510. Rest of Asia-Pacific Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 511. Rest of Asia-Pacific Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 512. Rest of Asia-Pacific Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 513. Europe Genetic Testing Sales, by Country K Unit (2025-2030)
  • Table 514. Europe Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 515. Europe Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 516. Europe Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 517. Europe Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 518. Germany Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 519. Germany Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 520. Germany Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 521. Germany Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 522. France Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 523. France Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 524. France Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 525. France Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 526. Italy Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 527. Italy Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 528. Italy Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 529. Italy Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 530. United Kingdom Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 531. United Kingdom Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 532. United Kingdom Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 533. United Kingdom Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 534. Netherlands Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 535. Netherlands Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 536. Netherlands Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 537. Netherlands Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 538. Rest of Europe Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 539. Rest of Europe Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 540. Rest of Europe Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 541. Rest of Europe Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 542. MEA Genetic Testing Sales, by Country K Unit (2025-2030)
  • Table 543. MEA Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 544. MEA Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 545. MEA Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 546. MEA Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 547. Middle East Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 548. Middle East Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 549. Middle East Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 550. Middle East Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 551. Africa Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 552. Africa Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 553. Africa Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 554. Africa Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 555. North America Genetic Testing Sales, by Country K Unit (2025-2030)
  • Table 556. North America Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 557. North America Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 558. North America Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 559. North America Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 560. United States Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 561. United States Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 562. United States Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 563. United States Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 564. Canada Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 565. Canada Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 566. Canada Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 567. Canada Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 568. Mexico Genetic Testing Sales, by Type K Unit (2025-2030)
  • Table 569. Mexico Genetic Testing Sales, by Application K Unit (2025-2030)
  • Table 570. Mexico Genetic Testing Sales, by Clinical Indication K Unit (2025-2030)
  • Table 571. Mexico Genetic Testing Sales, by End User K Unit (2025-2030)
  • Table 572. Research Programs/Design for This Report
  • Table 573. Key Data Information from Secondary Sources
  • Table 574. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genetic Testing: by Type USD Million (2018-2023)
  • Figure 5. Global Genetic Testing: by Application USD Million (2018-2023)
  • Figure 6. Global Genetic Testing: by Clinical Indication USD Million (2018-2023)
  • Figure 7. Global Genetic Testing: by End User USD Million (2018-2023)
  • Figure 8. South America Genetic Testing Share (%), by Country
  • Figure 9. Asia Pacific Genetic Testing Share (%), by Country
  • Figure 10. Europe Genetic Testing Share (%), by Country
  • Figure 11. MEA Genetic Testing Share (%), by Country
  • Figure 12. North America Genetic Testing Share (%), by Country
  • Figure 13. Global Genetic Testing: by Type K Unit (2018-2023)
  • Figure 14. Global Genetic Testing: by Application K Unit (2018-2023)
  • Figure 15. Global Genetic Testing: by Clinical Indication K Unit (2018-2023)
  • Figure 16. Global Genetic Testing: by End User K Unit (2018-2023)
  • Figure 17. South America Genetic Testing Share (%), by Country
  • Figure 18. Asia Pacific Genetic Testing Share (%), by Country
  • Figure 19. Europe Genetic Testing Share (%), by Country
  • Figure 20. MEA Genetic Testing Share (%), by Country
  • Figure 21. North America Genetic Testing Share (%), by Country
  • Figure 22. Global Genetic Testing share by Players 2023 (%)
  • Figure 23. Global Genetic Testing share by Players (Top 3) 2023(%)
  • Figure 24. Global Genetic Testing share by Players (Top 5) 2023(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Transgenomic, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Transgenomic, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 29. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 30. 23 & Me (United States) Revenue, Net Income and Gross profit
  • Figure 31. 23 & Me (United States) Revenue: by Geography 2023
  • Figure 32. Sequenom, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Sequenom, Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 35. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 36. Biocartis SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. Biocartis SA (Switzerland) Revenue: by Geography 2023
  • Figure 38. Illumina Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Illumina Inc. (United States) Revenue: by Geography 2023
  • Figure 40. 454 Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 41. 454 Life Sciences (United States) Revenue: by Geography 2023
  • Figure 42. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 43. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 44. Luminex Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 45. Luminex Corporation (United States) Revenue: by Geography 2023
  • Figure 46. Affymetrix Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 47. Affymetrix Inc. (United States) Revenue: by Geography 2023
  • Figure 48. Agilent Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 49. Agilent Technologies Inc. (United States) Revenue: by Geography 2023
  • Figure 50. Cephide Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 51. Cephide Inc. (United States) Revenue: by Geography 2023
  • Figure 52. Beckman Coulter Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 53. Beckman Coulter Inc. (United States) Revenue: by Geography 2023
  • Figure 54. Gene Dx LLC (United States) Revenue, Net Income and Gross profit
  • Figure 55. Gene Dx LLC (United States) Revenue: by Geography 2023
  • Figure 56. Global Genetic Testing: by Type USD Million (2025-2030)
  • Figure 57. Global Genetic Testing: by Application USD Million (2025-2030)
  • Figure 58. Global Genetic Testing: by Clinical Indication USD Million (2025-2030)
  • Figure 59. Global Genetic Testing: by End User USD Million (2025-2030)
  • Figure 60. South America Genetic Testing Share (%), by Country
  • Figure 61. Asia Pacific Genetic Testing Share (%), by Country
  • Figure 62. Europe Genetic Testing Share (%), by Country
  • Figure 63. MEA Genetic Testing Share (%), by Country
  • Figure 64. North America Genetic Testing Share (%), by Country
  • Figure 65. Global Genetic Testing: by Type K Unit (2025-2030)
  • Figure 66. Global Genetic Testing: by Application K Unit (2025-2030)
  • Figure 67. Global Genetic Testing: by Clinical Indication K Unit (2025-2030)
  • Figure 68. Global Genetic Testing: by End User K Unit (2025-2030)
  • Figure 69. South America Genetic Testing Share (%), by Country
  • Figure 70. Asia Pacific Genetic Testing Share (%), by Country
  • Figure 71. Europe Genetic Testing Share (%), by Country
  • Figure 72. MEA Genetic Testing Share (%), by Country
  • Figure 73. North America Genetic Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Transgenomic, Inc. (United States)
  • GE Healthcare (United States)
  • 23 & Me (United States)
  • Sequenom, Inc. (United States)
  • Abbott Laboratories (United States)
  • Biocartis SA (Switzerland)
  • Illumina Inc. (United States)
  • 454 Life Sciences (United States)
  • Bio-Rad Laboratories (United States)
  • Luminex Corporation (United States)
  • Affymetrix Inc. (United States)
  • Agilent Technologies Inc. (United States)
  • Cephide Inc. (United States)
  • Beckman Coulter Inc. (United States)
  • Gene Dx LLC (United States)
Additional players considered in the study are as follows:
Invitae (United States) , Pathway Genomics (United States) , Counsyl, Inc. (United States) , Asper Biotech (Europe) , GenePlanet (Europe) , Ambry Genetics (United States) , Others
Select User Access Type

Key Highlights of Report


Feb 2024 208 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Genetic Testing Market Quantitative research analysis
Global Genetic Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Transgenomic, Inc. (United States), GE Healthcare (United States), 23 & Me (United States), Sequenom, Inc. (United States), Abbott Laboratories (United States), Biocartis SA (Switzerland), Illumina Inc. (United States), 454 Life Sciences (United States), Bio-Rad Laboratories (United States), Luminex Corporation (United States), Affymetrix Inc. (United States), Agilent Technologies Inc. (United States), Cephide Inc. (United States), Beckman Coulter Inc. (United States) and Gene Dx LLC (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The shift of focus from clinical science to bioinformatics and growing popularity of these techniques, leading to high rate of adoption of genetic testing technology." is seen as one of major influencing trends for Genetic Testing Market during projected period 2023-2030.
The Genetic Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Genetic Testing Market Report?

Have a Query? Click Here

Other Related Reports

Cardiac Marker Comprehensive Study by Type (Cardiac Troponin, Creatinine Kinase, CK-MB, Myoglobin), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclero...
$ 3450
Radiology Information System Comprehensive Study by Type (Integrated Radiology Information System, Standalone Radiology Information System), Application (Hospitals, Office based Physicians, Emergency...
$ 3750
Ablation Technologies Comprehensive Study by Type (Radiofrequency Ablation, Laser/Light Ablation, Cryoablation Ablation, Microwave Ablation, Hydrothermal Ablation, Others), Application (Cardiovascula...
$ 3450
Piezoelectric Biosensors Comprehensive Study by Type (Piezoelectric Ceramics, Single Crystal Materials, Others), Application (Medical Testing, Food Toxicity, Industrial Process, Environmental and Agr...
$ 3650
Healthcare Automation Comprehensive Study by Application (Diagnostics and Monitoring (Automated Image Analysis, Automated Imaging, and Point-Of-Care Testing), Pharmacy and Laboratory, Therapeutic Aut...
$ 3750
E-Prescribing System Comprehensive Study by Type (Integrated systems, Stand-alone systems), Application (Office-based physicians, Hospitals, Other), Deployment Type (On-premises, Cloud-Based), Platfo...
$ 3450